MetrioPharm AG, a clinical stage biopharmaceutical development company based in Zurich with a subsidiary in Berlin, Germany, has developed a platform of small molecule drug candidates (oral and i.v.) which targets the modulation of immune cell metabolism without suppressing the immune system.
Products, services, technology
MetrioPharm’s drug candidates have a unique first-in-class self-regulating mechanism of action and have demonstrated broad anti-inflammatory and host-directed anti-infective efficacy with an outstanding safety profile in various preclinical and clinical studies.
Licensing & strategic partnerships in Duchenne, Juvenile Idiopathic Arthritis, COVID-19, Psoriasis, Multiple Sclerosis, Rheumatoid Arthritis, Inflammatory Bowel Disease, SIRS, MDRS, ARDS and Sepsis. Participation in MetrioPharm's upcoming equity financing round for up to USD 40m in H1/2023.
Our platform will have a strong social impact in countries with low-to-middle income as we combine low-cost, widely used & validated generic drugs with MP1032 in fixed-dose-combinations to create a new class of affordable drugs with potentially better efficacy/safety than high-priced biologic drugs.
Biotech and phamaceutical companies which put the patients interest first and are not only successful in commercial terms but also have a strong social impact in countries with low-to-middle income as well as develop drugs for smaller patient populations with high medical need.
Pharmaceutical and biotech companies and patient organisations as potential collaboration partners as well as knowledgable investors and grant providers understanding the risks and potential rewards of ethical drug development